1
|
Thakkar JP, Chew L and Villano JL: Primary
CNS germ cell tumors: Current epidemiology and update on treatment.
Med Oncol. 30:4962013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Dufour C, Guerrini-Rousseau L and Grill J:
Central nervous system germ cell tumors: An update. Curr Opin
Oncol. 26:622–626. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Subbiah V, Meric-Bernstam F, Mills GB,
Shaw KR, Bailey AM, Rao P, Ward JF and Pagliaro LC: Next generation
sequencing analysis of platinum refractory advanced germ cell tumor
sensitive to Sunitinib (Sutent®) a
VEGFR2/PDGFRβ/c-kit/FLT3/RET/CSF1R inhibitor in a phase II trial. J
Hematol Oncol. 7:522014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Sakuma Y, Sakurai S, Oguni S, Hironaka M
and Saito K: Alterations of the c-kit gene in testicular germ cell
tumors. Cancer Sci. 94:486–491. 2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Cruse G, Metcalfe DD and Olivera A:
Functional deregulation of KIT: Link to mast cell proliferative
diseases and other neoplasms. Immunol Allergy Clin North Am.
34:219–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rossi P: Transcriptional control of KIT
gene expression during germ cell development. Int J Dev Biol.
57:179–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Yamada T, Hasegawa S, Inoue Y, Date Y,
Yamamoto N, Mizutani H, Nakata S, Matsunaga K and Akamatsu H:
Wnt/β-catenin and kit signaling sequentially regulate melanocyte
stem cell differentiation in UVB-induced epidermal pigmentation. J
Invest Dermatol. 133:2753–2762. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Reber LL, Marichal T and Galli SJ: New
models for analyzing mast cell functions in vivo. Trends
Immunol. 33:613–625. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Huizinga JD, Thuneberg L, Klüppel M,
Malysz J, Mikkelsen HB and Bernstein A: W/kit gene required for
interstitial cells of Cajal and for intestinal pacemaker activity.
Nature. 373:347–349. 1995. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Broudy VC: Stem cell factor and
hematopoiesis. Blood. 90:1345–1364. 1997.PubMed/NCBI
|
12
|
Rammohan A, Sathyanesan J, Rajendran K,
Pitchaimuthu A, Perumal SK, Srinivasan U, Ramasamy R, Palaniappan R
and Govindan M: A gist of gastrointestinal stromal tumors: A
review. World J Gastrointest Oncol. 5:102–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Coffey J, Linger R, Pugh J, Dudakia D,
Sokal M, Easton DF, Bishop Timothy D, Stratton M, Huddart R and
Rapley EA: Somatic KIT mutations occur predominantly in seminoma
germ cell tumors and are not predictive of bilateral disease:
Report of 220 tumors and review of literature. Genes Chromosomes
Cancer. 47:34–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Hoei-Hansen CE, Kraggerud SM, Abeler VM,
Kaern J, Rajpert-De Meyts E and Lothe RA: Ovarian dysgerminomas are
characterised by frequent KIT mutations and abundant expression of
pluripotency markers. Mol Cancer. 6:122007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Terada T: Mediastinal seminoma with
multiple KIT gene mutations. Pathology. 41:695–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Yuan F, Shi M, Ji J, Shi H, Zhou C, Yu Y,
Liu B, Zhu Z and Zhang J: KRAS and DAXX/ATRX gene mutations are
correlated with the clinicopathological features, advanced
diseases, and poor prognosis in Chinese patients with pancreatic
neuroendocrine tumors. Int J Biol Sci. 10:957–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Sakuma Y, Sakurai S, Oguni S, Satoh M,
Hironaka M and Saito K: c-kit gene mutations in intracranial
germinomas. Cancer Sci. 95:716–720. 2004. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kamakura Y, Hasegawa M, Minamoto T,
Yamashita J and Fujisawa H: C-kit gene mutation: Common and widely
distributed in intracranial germinomas. J Neurosurg. 104(Suppl):
173–180. 2006.PubMed/NCBI
|
19
|
Miettinen M and Lasota J: KIT (CD117): A
review on expression in normal and neoplastic tissues, and
mutations and their clinicopathologic correlation. Appl
Immunohistochem Mol Morphol. 13:205–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
20
|
McIntyre A, Summersgill B, Grygalewicz B,
Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R,
Cooper C, et al: Amplification and overexpression of the KIT gene
is associated with progression in the seminoma subtype of
testicular germ cell tumors of adolescents and adults. Cancer Res.
65:8085–8089. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Willmore-Payne C, Holden JA, Chadwick BE
and Layfield LJ: Detection of c-kit exons 11- and 17-activating
mutations in testicular seminomas by high-resolution melting
amplicon analysis. Mod Pathol. 19:1164–1169. 2006. View Article : Google Scholar : PubMed/NCBI
|
22
|
Cheng L, Roth LM, Zhang S, Wang M, Morton
MJ, Zheng W, Karim Abdul FW, Montironi R and Lopez-Beltran A: KIT
gene mutation and amplification in dysgerminoma of the ovary.
Cancer. 117:2096–2103. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lennartsson J and Rönnstrand L: Stem cell
factor receptor/c-Kit: From basic science to clinical implications.
Physiol Rev. 92:1619–1649. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Bodemer C, Hermine O, Palmérini F, Yang Y,
Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L,
Georgin-Lavialle S, Cohen-Akenine A, et al: Pediatric mastocytosis
is a clonal disease associated with D816V and other activating
c-KIT mutations. J Invest Dermatol. 130:804–815. 2010. View Article : Google Scholar : PubMed/NCBI
|
25
|
Corbin AS, O'Hare T, Gu Z, Kraft IL,
Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW,
et al: KIT signaling governs differential sensitivity of mature and
primitive CML progenitors to tyrosine kinase inhibitors. Cancer
Res. 73:5775–5786. 2013. View Article : Google Scholar : PubMed/NCBI
|
26
|
Calibasi G, Baskin Y, Alyuruk H, Cavas L,
Oztop I, Sagol O, Atila K, Ellidokuz H and Yilmaz U: Molecular
analysis of the KIT gene in gastrointestinal stromal tumors with
novel mutations. Appl Immunohistochem Mol Morphol. 22:37–45. 2014.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, et al: Kinase mutations and imatinib
response in patients with metastatic gastrointestinal stromal
tumor. J Clin Oncol. 21:4342–4349. 2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Corless CL, Ballman KV, Antonescu CR,
Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD,
Demetri GD, Heinrich MC, et al: Pathologic and molecular features
correlate with long-term outcome after adjuvant therapy of resected
primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol.
32:1563–1570. 2014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hou YY, Tan YS, Sun MH, Wei YK, Xu JF, Lu
SH, A-Ke-Su SJ, Zhou YN, Gao F, Zheng AH, et al: C-kit gene
mutation in human gastrointestinal stromal tumors. World J
Gastroenterol. 10:1310–1314. 2004.PubMed/NCBI
|
30
|
Tetzlaff ED and Davey MP: Optimizing
adherence to adjuvant imatinib in gastrointestinal stromal tumor. J
Adv Pract Oncol. 4:238–250. 2013.PubMed/NCBI
|